Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CAMBRIDGE, Mass., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced it will present at three events during the month of December. Oppenheimer 25th...
-
Clinical data from Phase 1 studies of MM-398 and MM-151 presented First public presentation of MM-131, a novel bi-specific antibody targeting the c-Met signaling pathway BARCELONA, Spain, Nov....
-
CAMBRIDGE, Mass., Nov. 19, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the U.S. Food and Drug Administration (FDA) has granted MM-398 (nanoliposomal...
-
CAMBRIDGE, Mass., Nov. 17, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the election of Vivian S. Lee, Ph.D., M.D., M.B.A. to its Board of Directors. Lee...
-
CAMBRIDGE, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that it will present research on three of its therapeutic candidates at the 2014...
-
CAMBRIDGE, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK), a biopharmaceutical company discovering, developing and preparing to commercialize innovative...
-
CAMBRIDGE, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the first patient has been enrolled in a Phase 1 clinical study of MM-398...
-
CAMBRIDGE, Mass., Nov. 5, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to...
-
CAMBRIDGE, Mass., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that the company will host its Third Quarter 2014 Investor Conference Call and webcast...
-
Data Presented as Part of Meta-Analysis Showing MM-121's Favorable Impact on Progression Free Survival in 38-54 Percent of Patients With Ovarian, Lung and Breast Cancers Across Three Phase 2...